Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)
Ani Pharmaceuticals (ANIP) posted Restructuring Costs of $2000.0 for Q2 2023, down 99.82% sequentially from $1.1 million in Q1 2023, and down 99.92% YoY from $2.6 million in Q2 2022.
Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023) Analysis & Trends
Ani Pharmaceuticals has reported Restructuring Costs for 2 years, with the latest figure at $2000.0 in Q2 2023.
- Quarterly Restructuring Costs fell 99.92% year-over-year to $2000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $2000.0 (down 99.97% YoY) and the FY2023 annual result came in at $1.1 million, down 80.07% from the prior year.
- Restructuring Costs fell to $2000.0 in Q2 2023 per ANIP's latest filing, from $1.1 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $2.6 million in Q2 2022 and troughed at $2000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 2.57 Mn |